华东医药(000963.SZ)：依达拉奉片收到药品注册受理通知书

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received a notice of acceptance from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - The application for Edaravone tablets, with the development code TTYP01, has been officially accepted by the NMPA [1] - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]